CSG Shares Under Pressure as Barclays Initiates Cautious Coverage, Munitions Weakness Clouds Record Half-Year

Barclays initiates with Underweight and €18 target as defence stock pulls back 3% after 28.6% rally, despite strong H1 results and record €46B backlog.

The defence contractor's stock is giving back some of its recent gains on Monday, trading at €17.56 — a 3.02 percent slide from Friday's close — after Barclays kicked off coverage with an "Underweight" rating and an €18.00 price target. That target sits barely above the current share price and well below the ambitions of other banks tracking the Prague-based group.

The pullback follows a remarkable 28.60 percent run-up over the past 30 days, a rally that had recouped a meaningful portion of the losses from January's record high of €36.05. Even with Monday's setback, the stock remains firmly above its June low, keeping the medium-term uptrend intact.

A Tale of Two Businesses

The Barclays caution lands at an awkward moment — just days after the company posted headline numbers that, on the surface, look exceptional. First-half revenue climbed 17.2 percent to €3.251 billion, while operating EBIT rose 12.7 percent to €784 million, translating to a 24.1 percent margin. Net profit jumped a striking 84.8 percent to €572.3 million.

Both revenue and EBIT beat consensus forecasts of €3.14 billion and €764 million, respectively. The second quarter was particularly strong: revenue grew 20.3 percent to roughly €1.71 billion, EBIT advanced 16.5 percent to €413 million, and net profit nearly doubled with a 94.2 percent surge to €272 million.

Yet beneath those figures sits a glaring weak spot. The Ammo+ munitions division saw first-half revenue fall 11.5 percent to €631 million, down from €713 million a year earlier. Operating profit in the unit dropped even more sharply, sliding 26.7 percent to €51 million. The division's operating margin of 8.1 percent, while down year-on-year, marks a notable improvement from the 4.5 percent posted in the first quarter — a sign that the worst may be over.

Some cushion came from US demand: a contract with the FBI for rifle ammunition is worth $77 million, and combined orders from US federal and law enforcement agencies total roughly $100 million. Those wins bolster the order book but haven't fully offset the core business's decline.

Record Order Book and Expansion Drive

The group's overall backlog, including the pipeline under negotiation, reached a record €46 billion by June 30, up from €44 billion in March, with the Land Systems division now the largest single contributor.

Management confirmed its full-year guidance of €7.4 billion to €7.6 billion in revenue and an EBIT margin between 24 and 25 percent.

The expansion agenda remains aggressive. The company has acquired the Gnaschwitz industrial site in Germany, where an initial investment of more than €100 million will build production capacity for nitroglycerin and munitions components. A new Slovakian joint venture, Danube Defence Systems, has been established with Turkish partner FNSS — CSG holds 51 percent — to manufacture the CFL-120 Karpat medium tank and other vehicles. A separate partnership with South Africa's Reunert will create Fuchs Electronics Europe, producing electronic fuses for large-calibre ammunition in Dubnica nad Váhom.

The group also refinanced its credit lines, cutting financing costs by 125 to 150 basis points and extending maturities to six years.

Analyst Divergence Widens

The Barclays stance, from analyst Afonso Osorio, stands in sharp contrast to the bullish camp. JPMorgan's Dominic Chopping reaffirmed an "Overweight" rating on Friday with a €50.00 price target, describing the half-year results as the third solid set of numbers since the January 2026 IPO. J&T Banka also initiated coverage on Friday with a "Buy" recommendation. Jefferies' Chloe Lemarie had confirmed her buy rating on August 4, nudging her price target up slightly to $28.82 from $28.78.

The gulf between the €18 and €50 price targets underscores how divided the street remains on how to value the group's rapid growth against the heavy capital commitments tied to acquisitions and joint ventures. For now, the more sceptical reading is setting the tone.

Beyond the balance sheet, CSG has been broadening its technological footprint. In early August, it completed the acquisition of a strategic minority stake in Canadian firm North Vector Dynamics, valued at over $90 million, which supplies hypersonic and air-defence technologies. The company also appointed Ben Hudson, formerly of Hanwha, to its board.

Investors will get the next data point on November 11 with third-quarter figures, while the group presents at the MSPO defence fair in Kielce from September 8 to 11. Whether the Ammo+ weakness proves temporary or structural remains the key question hanging over the stock — the sequential margin recovery offers some comfort, but the market's muted reaction suggests the jury is still out.